Form 4: Akari Therapeutics Director Robert Bazemore Granted 5,000,000 Stock Options

Director Robert B. Bazemore of Akari Therapeutics Plc was granted 5,000,000 non-qualified stock options under the company's 2023 Equity Incentive Plan.

Summary

• Robert B. Bazemore, a director of Akari Therapeutics Plc, was granted 5,000,000 non-qualified stock options on September 17, 2024.
• The options were granted under the Issuer's 2023 Equity Incentive Plan.
• The exercise price of the stock options is $0.001655 per ordinary share.
• The options vest in three equal installments, starting on the date of the first Annual General Meeting (AGM) following the grant date, and then on the dates of the second and third AGMs, contingent upon continued service with the Issuer.
• The stock options expire on September 17, 2034.
• Bazemore has also granted power of attorney to Samir R. Patel and Wendy F. DiCicco to act on his behalf in matters related to securities filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and generally viewed as a positive incentive for management. There are no immediate negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with those of shareholders. The size of the grant and the vesting schedule are typical for director compensation in similar companies.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years is also common, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like BioNTech or Moderna also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates